Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COM701 Triple Combination in Advanced Solid Tumors
NCT04570839Phase 2Completed
- Sponsor
- Compugen Ltd.
- Start
- Aug 2020
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of COM701 in ovarian cancer, endometrial cancer (EC), head and neck cancer (HNC), solid tumor, sponsored by Compugen Ltd.. Started Aug 2020; status: completed.
02
Drugs
COM701
03
Conditions
ovarian cancerendometrial cancer (EC)head and neck cancer (HNC)solid tumor
Beyond the preview
Go deeper on NCT04570839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04570839.